AlphaStar Capital Management »

Fs Global Cr Opportunitie Fda shares owned by AlphaStar Capital Management

Quarter-by-quarter ownership of Fs Global Cr Opportunitie Fda (FSCO) shares owned by AlphaStar Capital Management from 13F filings

Historical chart of AlphaStar Capital Management investment in Fs Global Cr Opportunitie Fda

Tip: Access up to 7 years of quarterly data

All positions including Fs Global Cr Opportunitie Fda held by AlphaStar Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fs Global Cr Opportunitie Fda by AlphaStar Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $488k 86k 5.67
2023-09-30 $494k 91k 5.42
2023-06-30 $207k 44k 4.75
2023-03-31 $110k 25k 4.44

More positions owned by AlphaStar Capital Management

Spdr Ser Tr Prtflo S&p500 Gw (SPYG)
Spdr Ser Tr Portfolio S&p500 (SPLG)
Spdr Index Shs Fds Portfolio Devlpd (SPDW)
Ishares Tr 0-3 Mnth Treasry (SGOV)
Spdr Ser Tr Prtflo S&p500 Vl (SPYV)
Schwab Strategic Tr Us Aggregate B (SCHZ)
Select Sector Spdr Tr Technology (XLK)
Select Sector Spdr Tr Sbi Cons Discr (XLY)
Spdr Ser Tr Portfolio S&p400 (SPMD)
Etf Ser Solutions Lha Mkt St Tactl (MSTB)
Vanguard Index Fds Growth Etf (VUG)
Select Sector Spdr Tr Financial (XLF)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Spdr Index Shs Fds Portfolio Emg Mk (SPEM)
Vanguard Index Fds Value Etf (VTV)

View all positions for AlphaStar Capital Management

Top funds holding Fs Global Cr Opportunitie Fda

Commonwealth Equity Services
Nomura Holdings
Cambridge Investment Research Advisors
Thomas J. Herzfeld Advisors
Saba Capital Management
Wagner Wealth Management
Penserra Capital Management
Advisor Group Holdings
H D Vest Advisory Services
Rockefeller Capital Management
Royal Bank of Canada
Kestra Advisory Services
Ellis Investment Partners
Prime Capital Investment Advisors
Feltz Wealth PLAN

View all funds holding Fs Global Cr Opportunitie Fda